

FAX



COPY



GlaxoSmithKline

To Examiner B. Robinson, Group 1625
.....
Company USPTO
.....
Fax 703-872-9306
.....
From Valerie L. Phillips
.....
Tel 919-483-8223
.....
E-mail Vlp47157@gsk.com
.....
Date 22-Feb-2002 Pages including cover 21
.....
Subject PG3602USW
.....

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

RE: Response to official action dated 12/04/2001.
Applicant: I Campbell et al.
Serial No. 09/830,836
Filed 1 May 2001
Group Art 1625
Examiner B. Robinson
Title: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2-INHIBITORS

Items being sent:

1. Transmittal and response to official action dated 12/04/2001
2. Copies of postcard, IDS and PTO-1449 submitted 9/28/01

NOTE: Copies of references cited in IDS dated 9/28/01 being mailed via US Mail under separate cover.

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

COPY



DOCKET NO.:


SERIAL NO.:

TITLE:

PG 3602 USW
09/830 836
Nitrazotopyridine derivatives as selective Cox-2...

The date stamp of the Patent Office hereon may be considered as the date on which papers indicated below are received.

- ☐ Application _____ pages _____ claims
- ☐ Abstract
- ☐ Assignment w/Coverletter
- ☐ Drawings (_____ sheets)
- ☐ Declaration/Oath w/Power of Attorney ☐ Unexecuted ☐ Executed
- ☒ Fee Authorization & Deposit Account Copy
- ☒ IDS-Publication Disclosure (37 CFR 1.56) ☐ w/o References ☒ w/References
- ☐ Amendment (_____)
- ☐ Petition for Extension of Time ☐ 1mo ☐ 2mo ☐ 3mo ☐ 4mo
- ☐ Issue Fee Transmittal
- ☐ Notice of Appeal
- ☐ Appeal Brief
- ☐ Req. for Oral Hearing
- ☒ Certificate of Mailing ☒ Express Mail ☒ 1st Class



Resp to Restriction Request

9/28/01

CME



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1625

In re application of: Campbell et al.

Serial No.: 09/830,836

Group Art Unit: 1625

Filed: May 1, 2001

Examiner: B. Robinson

COPY

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [X] Copies of the references are enclosed.
- [] Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
- [] A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- [] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.
- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents, Washington, D.C. 20231.

Date: 9/28/01

Cynthia M. Edwards
Cynthia M. Edwards

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☒ A duplicate copy of this paper is attached.

COPY

Respectfully Submitted,




Lorie Ann Morgan

Attorney of Record:

Registration No. 38,181

DATED: 9/28/01
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO. PG3602USW	SERIAL NO. 09/830,836
		APPLICANT CAMPBELL et al.	
		FILING DATE May 1, 2001	GROUP 1625

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5498774	Mar 12 1996	Mitsudera et al			
	AB	5990148	Nov 23 1999	Isakson et al			
	AC	5700816	Dec 23 1997	Isakson et al			
	AD	6136839	Oct 24 2000	Isakson et al			
	AE	5552422	Sept 3 1996	Gauthier et al			
	AF	5155114	Oct 13 1992	Shiokawa et al			
	AG	5296490	Mar 22 1994	Shiokawa et al			
	AH	4985444	Jan 15 1991	Shiokawa et al			
	AI	5300478	Apr 5 1994	Michaely et al			

COPY

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	BE WO 95/00501 ✓	05 Jan 1995	PCT			
	BF WO 0114375 ✓	01 Mar 2001	PCT			
	BG EP 0404 190A1 ✓	27 Dec 1990	EPO			
	BH EP 0404 190B1 ✓	27 Dec 1990	EPO			
	BI WO 9119497 ✓	26 Dec 1991	PCT			
	BJ WO 9641625 ✓	27 Dec 1996	PCT			
	BK WO 9641626 ✓	27 Dec 1996	PCT			
	BL WO 9641645 ✓	27 Dec 1996	PCT			
	BM WO 9100092	10 Jan 1991	PCT			
	BN EP 0467248B1	22 Jan 1992	EPO			
	BO EP 0364204A1	18 Apr 1990	PCT			

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

CE	Akahane, A. et al., "Discovery of 6-Oxo-3-(2-phenylpyrazolo [1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic Acid (FK 838): A Novel Non-Xanthine Adenosine A ₁ Receptor Antagonist with Potent Diuretic Activity", JOURNAL OF MEDICINAL CHEMISTRY, Vol. 42, no. 5, 11 Mar 1999, pp. 779-784.
----	--

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.